Hims & Hers Health (NYSE:HIMS) Rating Reiterated by Jefferies Financial Group

Hims & Hers Health (NYSE:HIMS)‘s stock had its “hold” rating reiterated by equities research analysts at Jefferies Financial Group in a report issued on Tuesday, MarketBeat.com reports. They presently have a $15.00 price target on the stock, down from their prior price target of $17.00. Jefferies Financial Group’s target price points to a potential upside of 21.16% from the company’s current price.

Several other equities research analysts also recently weighed in on the stock. Canaccord Genuity Group initiated coverage on shares of Hims & Hers Health in a report on Wednesday, April 10th. They issued a “buy” rating and a $20.00 price objective for the company. Leerink Partnrs reaffirmed a “market perform” rating on shares of Hims & Hers Health in a report on Monday, February 26th. Guggenheim upped their price objective on shares of Hims & Hers Health from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Canaccord Genuity Group began coverage on shares of Hims & Hers Health in a report on Wednesday, April 10th. They issued a “buy” rating and a $20.00 price target for the company. Finally, TheStreet raised shares of Hims & Hers Health from a “d” rating to a “c” rating in a report on Monday, March 4th. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Moderate Buy” and an average target price of $14.85.

Hims & Hers Health Price Performance

HIMS stock opened at $12.38 on Tuesday. The firm has a fifty day moving average price of $13.42 and a two-hundred day moving average price of $9.78. The firm has a market cap of $2.65 billion, a price-to-earnings ratio of -112.55 and a beta of 0.91. Hims & Hers Health has a 1-year low of $5.65 and a 1-year high of $17.16.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, February 26th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.03. The business had revenue of $246.60 million during the quarter, compared to analyst estimates of $245.84 million. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The company’s quarterly revenue was up 47.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.05) earnings per share. As a group, analysts expect that Hims & Hers Health will post 0.1 EPS for the current fiscal year.

Insider Activity

In related news, CEO Andrew Dudum sold 15,100 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $9.01, for a total value of $136,051.00. Following the transaction, the chief executive officer now owns 51,653 shares in the company, valued at $465,393.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO Andrew Dudum sold 15,100 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $9.01, for a total value of $136,051.00. Following the transaction, the chief executive officer now owns 51,653 shares in the company, valued at $465,393.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Soleil Boughton sold 63,621 shares of the stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $15.17, for a total value of $965,130.57. Following the completion of the transaction, the insider now owns 154,345 shares in the company, valued at approximately $2,341,413.65. The disclosure for this sale can be found here. Insiders have sold 675,838 shares of company stock worth $8,487,125 in the last 90 days. Company insiders own 31.63% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Large investors have recently added to or reduced their stakes in the stock. Graham Capital Management L.P. boosted its position in Hims & Hers Health by 39.4% during the third quarter. Graham Capital Management L.P. now owns 340,338 shares of the company’s stock worth $2,141,000 after purchasing an additional 96,277 shares during the period. Swiss National Bank boosted its position in Hims & Hers Health by 9.2% during the third quarter. Swiss National Bank now owns 309,200 shares of the company’s stock worth $1,945,000 after purchasing an additional 26,100 shares during the period. Vanguard Group Inc. boosted its position in Hims & Hers Health by 3.1% during the third quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock worth $88,857,000 after purchasing an additional 428,671 shares during the period. Bank of New York Mellon Corp boosted its position in Hims & Hers Health by 11.5% during the third quarter. Bank of New York Mellon Corp now owns 564,501 shares of the company’s stock worth $3,551,000 after purchasing an additional 58,288 shares during the period. Finally, Must Asset Management Inc. bought a new stake in Hims & Hers Health during the third quarter worth approximately $1,596,000. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.